Chester County News and Community Website
Trevena, Inc. (Nasdaq: TRVN), headquartered in Chesterbrook, PA, is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (NASDAQ: TRVN) has reported its Q3 2023 financial results, shedding light on a net loss attributable to common stockholders of $7.9 million, or …
Trevena Reports Promising Q3 2023 Results, Reveals Progress in TRV045 Studies and OLINVYK Sales Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, …
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023 Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) this week reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor …
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced the recent completion of the initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.
Trevena’s Exciting Findings: Insights on OLINVYK’s Impact on Respiratory Health to be Revealed at ASA Conference Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, recently announced receipt of a $15 million tranche under its non-dilutive ex-US royalty-based financing (the R-Bridge Financing). This tranche of funding …
Trevena Secures $15M Non-Dilutive Tranche and Shares Promising Business Update Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, recently announced preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for …
Trevena’s TRV045: Promising Results in Neuropathic Pain Trials with CNS Target Engagement Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, this week reported its financial results for the second quarter ended June 30, 2023 and provided an overview of its …
Trevena, Inc. Reports Q2 Financial Results and Highlights Promising Milestones Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, announced that Mark Corrigan, M.D. has recently been appointed to the Company’s Board of Directors, effective July 18, 2023.
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, announced new topline OLINVYK data from the ARTEMIS study.
Trevena Announces New Topline OLINVYK Data Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of …
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical Read More